Brady (BRC) Q3 2026 Earnings Call Transcript

Brady delivered record adjusted EPS of $1.50, up 23%, on 13.8% total sales growth and raised full-year adjusted EPS guidance to $5.20-$5.30 from $4.95-$5.15. Gross margin improved 50 bps to 51.8%, operating cash flow rose 30.7% to $78.2 million, and the company announced its 40th consecutive annual dividend increase plus ongoing buybacks. Management also detailed the Honeywell PSS acquisition, expected to close around August 1 and add about $0.80 of first-year adjusted EPS accretion before synergies.

Analysis

The core signal is not just a clean beat; it’s that Brady is moving from a “steady compounder” to a higher-quality growth platform. The combination of accelerating printer placements, wire-ID strength tied to data-center buildout, and expanded R&D spend suggests the company is taking share in higher-velocity end markets rather than merely harvesting price/mix. That matters because the PSS deal effectively adds a second growth engine with a different customer entry point, which should reduce reliance on any single product cycle and support a re-rating if execution holds through integration.

Second-order, the PSS acquisition looks more strategically important than the headline accretion implies. Even if year-one EPS lift is only modestly above current guidance, the real option value is a broader installed base, more channel leverage, and cross-sell into workflow-heavy accounts where Brady has historically been underpenetrated. The financing plan is conservative enough that the market likely underestimates how quickly equity holders can get both deleveraging and buybacks/dividend support at the same time, provided organic growth stays mid-single digits and free cash flow conversion remains high.

The main risk is not deal math; it’s execution friction colliding with a cyclical slowdown. A stronger dollar or a delayed/softening data-center buildout could compress the growth premium quickly, and PSS integration will temporarily raise the burden on management and board capacity. The board resignation optics are a reminder that this is a low-drama business only until a transformative M&A process introduces complexity; if any integration misstep causes SG&A to reaccelerate, the stock can de-rate faster than fundamentals deteriorate because the market is currently paying for perceived predictability.

Key Decisions for Investors

• Go long BRC on 1-3 month weakness post-runup; use pullbacks toward the prior breakout zone as entry. Risk/reward favors owning the name into the PSS close if the market is still discounting integration noise, with upside from multiple expansion plus accretion visibility.
• Pair trade: long BRC / short HON over the next 3-6 months. Brady is monetizing the asset strategically while HON loses a non-core productivity platform; the spread should widen if the market rewards cleaner capital allocation and punishes HON for simplification risk.
• Add BRC via call spreads rather than outright equity for a 6-9 month horizon. The setup is best if you want participation in re-rating from deal closure and guidance credibility, while capping downside if FX or macro stalls organic growth.
• Use a trailing stop if BRC loses its post-earnings momentum on volume. The stock is now trading on a higher-quality narrative, so a failure to hold recent highs would likely signal the market is skeptical of the PSS integration thesis.
• If already long, hold through the next two quarters but trim into strength after close if leverage/board commentary starts to dominate the story. The risk is a classic M&A digestion period where fundamentals stay good but sentiment cools before synergies become visible.